Sinphar Pharmaceutical Financials
| 1734 Stock | TWD 31.25 0.10 0.32% |
Sinphar |
Understanding current and past Sinphar Pharmaceutical Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Sinphar Pharmaceutical's financial statements are interrelated, with each one affecting the others. For example, an increase in Sinphar Pharmaceutical's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Sinphar Pharmaceutical's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Sinphar Pharmaceutical Co. Check Sinphar Pharmaceutical's Beneish M Score to see the likelihood of Sinphar Pharmaceutical's management manipulating its earnings.
Sinphar Pharmaceutical Stock Summary
Sinphar Pharmaceutical competes with GenMont Biotech, and Abnova Taiwan. ,Ltd., together with its subsidiaries, researches, develops, manufactures, and sells therapeutic drugs, health care foods, and medical beauty products in Taiwan and internationally. ,Ltd. was founded in 1977 and is headquartered in Yilan, Taiwan. SINPHAR PHARMACEUTICAL operates under Biotechnology classification in Taiwan and is traded on Taiwan Stock Exchange.| Instrument | Taiwan Stock View All |
| Exchange | Taiwan Stock Exchange |
| ISIN | TW0001734002 |
| Business Address | No 84, Zhongshan |
| Sector | Pharmaceuticals |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.sinphar.com.tw |
| Phone | 886 0 3958 1101 |
| Currency | TWD - New Taiwan Dollar |
You should never invest in Sinphar Pharmaceutical without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Sinphar Stock, because this is throwing your money away. Analyzing the key information contained in Sinphar Pharmaceutical's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Sinphar Pharmaceutical Key Financial Ratios
There are many critical financial ratios that Sinphar Pharmaceutical's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Sinphar Pharmaceutical reports annually and quarterly.| Return On Equity | 0.0444 | |||
| Return On Asset | 0.0207 | |||
| Number Of Employees | 26 | |||
| Beta | 0.79 | |||
| Z Score | 1.8 |
Sinphar Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Sinphar Pharmaceutical's current stock value. Our valuation model uses many indicators to compare Sinphar Pharmaceutical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Sinphar Pharmaceutical competition to find correlations between indicators driving Sinphar Pharmaceutical's intrinsic value. More Info.Sinphar Pharmaceutical Co is rated third in return on equity category among its peers. It also is rated third in return on asset category among its peers reporting about 0.47 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Sinphar Pharmaceutical Co is roughly 2.14 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Sinphar Pharmaceutical's earnings, one of the primary drivers of an investment's value.Sinphar Pharmaceutical Systematic Risk
Sinphar Pharmaceutical's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Sinphar Pharmaceutical volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Sinphar Pharmaceutical correlated with the market. If Beta is less than 0 Sinphar Pharmaceutical generally moves in the opposite direction as compared to the market. If Sinphar Pharmaceutical Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Sinphar Pharmaceutical is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Sinphar Pharmaceutical is generally in the same direction as the market. If Beta > 1 Sinphar Pharmaceutical moves generally in the same direction as, but more than the movement of the benchmark.
Sinphar Pharmaceutical November 27, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Sinphar Pharmaceutical help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Sinphar Pharmaceutical Co. We use our internally-developed statistical techniques to arrive at the intrinsic value of Sinphar Pharmaceutical Co based on widely used predictive technical indicators. In general, we focus on analyzing Sinphar Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Sinphar Pharmaceutical's daily price indicators and compare them against related drivers.
| Information Ratio | (0.18) | |||
| Maximum Drawdown | 18.28 | |||
| Value At Risk | (2.31) | |||
| Potential Upside | 0.9836 |
Additional Tools for Sinphar Stock Analysis
When running Sinphar Pharmaceutical's price analysis, check to measure Sinphar Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sinphar Pharmaceutical is operating at the current time. Most of Sinphar Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Sinphar Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sinphar Pharmaceutical's price. Additionally, you may evaluate how the addition of Sinphar Pharmaceutical to your portfolios can decrease your overall portfolio volatility.